EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2a

Ensembl ID : ENSLOCG00000010718
Gene Symbol: GABRB2A
1 Cross references
275 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSLOCG00000008344
Gene Symbol: GABRB3
3 Cross references
263 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSLOCG00000006079
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSLOCG00000012390
Gene Symbol: GABRG1
3 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSLOCG00000010690
Gene Symbol: GABRG2
3 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSLOCG00000008316
Gene Symbol: GABRG3
4 Cross references
278 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSLOCG00000007187
Gene Symbol: GABBR2
3 Cross references
241 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b-Like

Ensembl ID : ENSLOCG00000014889
Gene Symbol: LOC102694001
3 Cross references
184 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSLOCG00000014786
Gene Symbol: GIPR
2 Cross references
185 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSLOCG00000011822
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSLOCG00000015175
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSLOCG00000008160
Gene Symbol: GRIA2
3 Cross references
242 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).